Overview Header

Articles 2021.

A successful year in the Press for Arriello.

As 2021 closes and we look back on all we’ve achieved here at #TeamYellow, we can say for sure that it’s been another great success for articles that have been commissioned from our expert technical teams and our advisory board members.

 

The numbers:

  • 30 articles

  • 16 publications

  • 7 contributors

  • 1,302,538 circulation

January

Biosimilars – transforming global patient access to treatments. >>

The Biosimilars Opportunity – Driving Access to Treatment in Europe. >>

Gabriela Marton
Former Regulatory Affairs Director.

January

Navigating the European Market for Medical Cannabis. >>

 

Marketing Medical Cannabis in Europe. >>

Peter Kohut
Former Director of Drug Safety.

February

Medical cannabis and regulatory framework in Europe. >>

Carving out a slice of the European medical cannabis market. >>

March

Medical cannabis in Europe: a compelling opportunity. >>

May

Medical Cannabis in Europe – an opportunity ripe for exploitation. >>

Peter Kohut
Former Director of Drug Safety.
Ibrahim Said Abdeldayem
PV Specialist – Lead

June

Outsourcing clinical research support – time to put safety first. >>

Outsourcing clinical research support – time to put safety first. >>

Putting safety at the heart of clinical research outsourcing strategy. >>

Natalia Vlcek
Former EU QPPV.

June

Navigating International Pharmacovigilance. >>

Navigating pharmacovigilance complexity in the US and EU: notes for biotechs. >>

Dr. Eric Caugant
Safety Consultant and Advisor to Arriello.
Dr. Judith M. Sills
Safety Consultant and Advisor to Arriello.

July

International pharmacovigilance for biotechs: forming a strategy. >>

Pharmacovigilance for biotechs: navigating the differing requirements across the Atlantic. >>

Dr. Eric Caugant
Safety Consultant and Advisor to Arriello.
Dr. Judith M. Sills
Safety Consultant and Advisor to Arriello.

August

FDA vs EMA: biotechs & the challenges of international pharmacovigilance. >>

Dr. Judith M. Sills
Safety Consultant and Advisor to Arriello.
Dr. Eric Caugant
Safety Consultant and Advisor to Arriello.

September

Divided by a common language: PV differences between the UK & the US – Notes for Ambitious Biotechs. >>

Dr. Judith M. Sills
Safety Consultant and Advisor to Arriello.
Dr. Eric Caugant
Safety Consultant and Advisor to Arriello.

September

Mapping Out Pharma’s Regulatory Future in Europe. >>

Gabriela Marton
Former Regulatory Affairs Director.

October

Listicle: Experts on the differences between FDA and EMA regulations. >>

Dr. Eric Caugant
Safety Consultant and Advisor to Arriello.
Dr. Judith M. Sills
Safety Consultant and Advisor to Arriello.

October

Industry Organizations Assist Pharma During the Pandemic and Beyond. >>

The Evolving Biosimilar Approach. >>

Gabriela Marton
Former Regulatory Affairs Director.

October

Quality key in PV finds Arriello survey. >>

Quality deemed more critical than price as companies progress with PV case intake automation, 2021 Arriello UK/US survey finds. >>

Dr. John Price
Regulatory and Safety Consultant and Advisor to Arriello.

October

Clinical research outsourcing: prioritizing safety. >>

Natalia Vlcek
Former EU QPPV.

November

Quality overtakes cost as the priority as life sciences companies move to automate pharmacovigilance case intake. >>

Quality overtakes cost as the priority for automating PV reporting. >>

Quality More Important than Cost: Building the Business Case for PV Automation. >>

PV automation survey finds quality overtaking cost as top priority. >>

Dr. John Price
Regulatory and Safety Consultant and Advisor to Arriello.

November

Pharmacovigilance for biotechs. >>

Dr. Judith M. Sills
Safety Consultant and Advisor to Arriello.
Dr. Eric Caugant
Safety Consultant and Advisor to Arriello.